Objective:
To evaluate the New Drug Application (NDA) for K-911, an investigational eye drop for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Approach:
- NDA Submission: Kowa Pharmaceuticals America submitted an NDA for K-911 (bimatoprost grenod; NCX 470), which is designed to lower IOP.
- Mechanism of Action: K-911 is a nitric oxide-donating bimatoprost monotherapy that reduces IOP through two pathways: increasing conventional outflow and enhancing uveoscleral outflow.
- Clinical Trials: The NDA is supported by two pivotal Phase III trials, Mont Blanc and Denali, comparing K-911 with latanoprost.
Key Findings:
- K-911 is intended for once-daily use to lower IOP in patients with open-angle glaucoma or ocular hypertension.
- The FDA has set a target action date of April 30, 2027, for the NDA review.
- K-911 has not yet been approved by the FDA.
Limitations:
- K-911 remains investigational and has not received FDA approval.
- The long-term efficacy and safety profile of K-911 are yet to be established.
Conclusion:
If approved, Kowa anticipates launching K-911 in the US in the second half of 2027.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
